Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SCD | O00767 | 1/20 | 0.53 |
| ▸ | ILK | Q13418 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8994212 | 0.90 | APP (0.48) | APPMAPTSCDILKHTT | |
| SCHEMBL1984224 | 0.87 | APP (0.57) | APPMAPTSCDILKALK | |
| SCHEMBL1982367 | 0.84 | APP (0.53) | APPMAPTSCDILKALK | |
| SCHEMBL225021 | 0.82 | APP (0.54) | APPMAPTSCDALKGLA | |
| SCHEMBL1982639 | 0.82 | APP (0.66) | APPMAPTSCDGLAGAA | |
| SCHEMBL4784061 | 0.81 | MMP13 (0.63) | APPMAPTSCDILKHTT | |
| SCHEMBL13853571 | 0.80 | APP (0.67) | APPMAPTSCDGLAGAA | |
| SCHEMBL19243901 | 0.80 | SULT1A1 (0.62) | APPMAPTHTTSMN1; SMN2GLA | |
| SCHEMBL4730485 | 0.80 | APP (0.66) | APPILKALKGLAGAA | |
| SCHEMBL3200650 | 0.78 | SCD (0.53) | APPMAPTSCDAMY1AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | claimed |
| EP-0721336-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-07-17 | — | — | EP | claimed |
| WO-1995006469-A1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1995-03-09 | — | — | WO | claimed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| EP-0721336-B1 | BENZAZOLE COMPOUNDS FOR USE IN THERAPY | CANCER RES CAMPAIGN TECH (GB) | 1999-07-14 | — | — | EP | disclosed |
| US-5874431-A | ANTITUMOR AGENTS; BREAST CANCER | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | APP 24/4885MAPT 9/4885SCD 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.